Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 4(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06862739Phase 4Recruiting

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Role: lead

NCT07356609Not Yet Recruiting

Primary Care ERectile Function Outcome Registry for Men

Role: lead

NCT07346547Not Yet Recruiting

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

Role: lead

NCT07249788Phase 4Recruiting

Resmiterom Efficacy & Safety in Patients With MASH

Role: lead

NCT05804305Phase 2Completed

Misoprostol for NASH

Role: collaborator

NCT02386904Phase 4Unknown

Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy

Role: lead

All 6 trials loaded